Effects of isoflavone interventions on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials

[1] Chen P(2001)Osteoporosis prevention, diagnosis, and therapy JAMA 285 785-795

[2] Li Z(2016)Prevalence of osteoporosis in China: a meta-analysis and systematic review BMC Public Health 16 1039-2526

[3] Hu Y(2014)The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine J Bone Miner Res 29 2520-38

[4] Wright NC(2017)The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide Bone 104 29-2049

[5] Looker AC(2018)A comprehensive overview on osteoporosis and its risk factors Ther Clin Risk Manag 14 2029-1630

[6] Saag KG(2019)Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis J Clin Endocrinol Metab 104 1623-1118

[7] Curtis JR(2016)American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2016 – executive summary Endocr Pract 22 1111-1622

[8] Delzell ES(2019)Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline J Clin Endocrinol Metab 104 1595-44

[9] Randall S(2019)European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 30 3-1055

[10] Dawson-Hughes B(2018)Estrogen therapy for osteoporosis in the modern era Osteoporos Int 29 1049-205

[1] Chen P(2001)Osteoporosis prevention, diagnosis, and therapy JAMA 285 785-795

[2] Li Z(2016)Prevalence of osteoporosis in China: a meta-analysis and systematic review BMC Public Health 16 1039-2526

[3] Hu Y(2014)The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine J Bone Miner Res 29 2520-38

[4] Wright NC(2017)The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide Bone 104 29-2049

[5] Looker AC(2018)A comprehensive overview on osteoporosis and its risk factors Ther Clin Risk Manag 14 2029-1630

[6] Saag KG(2019)Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis J Clin Endocrinol Metab 104 1623-1118

[7] Curtis JR(2016)American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2016 – executive summary Endocr Pract 22 1111-1622

[8] Delzell ES(2019)Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline J Clin Endocrinol Metab 104 1595-44

[9] Randall S(2019)European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 30 3-1055

[10] Dawson-Hughes B(2018)Estrogen therapy for osteoporosis in the modern era Osteoporos Int 29 1049-205